Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Phase I/II of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
Sponsor: Dana-Farber Cancer Institute
A PHASE1/PHASE2 clinical study on Pancreatic Cancer, this trial is completed. The trial is conducted by Dana-Farber Cancer Institute and has accumulated 8 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jul 2018 — Feb 2019 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Dec 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .